A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

Status:
Terminated

Trial end date:
2020-02-27

Target enrollment:

Participant gender:

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).

Phase 2

Eli Lilly and Company